TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Yaron Werber, M.D., MBA

Managing Director, Health Care - Biotechnology

Liquid Biopsy Market Analysis

Dr. Yaron Werber is a Managing Director and senior research analyst on TD Cowen’s biotechnology team. In this role, Dr. Werber is responsible for providing analysis on large-, mid-, and small-cap biotechnology stocks. Dr. Werber has 20+ years of experience as a research analyst in the financial services industry and has served as an executive in a public biotechnology company.

Prior to rejoining TD Cowen, Dr. Werber was a founding team member, chief business and financial officer, treasurer and secretary of Ovid Therapeutics, a biotechnology company focused on developing transformative drugs for orphan disorders of the brain. In this role, Dr. Werber established and was responsible for all financial planning and reporting, business development, strategy, operations/IT and investor and public relations and human resources functionality. Dr. Werber also led negotiations to secure several pipeline compounds including an innovative partnership with Takeda Pharmaceutical Company, a deal that expanded Ovid’s pipeline and pioneered a novel approach for partnering the focused expertise of small biotech with big pharma.

This deal was chosen by Scrip as a finalist for the 2017 Best Partnership Alliance Award. In addition, Dr. Werber oversaw all financing activities and led a $75 million Series B round in 2015 and Ovid’s $75 million IPO in 2017. In that capacity, Dr. Werber was selected as an “Emerging Pharma Leader” by Pharmaceutical Executive magazine in 2017.

Prior to joining Ovid, Dr. Werber worked at Citi from 2004 to 2015, where he most recently served as a managing director and head of U.S. healthcare and biotech equity research. During his tenure at Citi, Dr. Werber led a team that conducted in-depth analyses of life science companies at all stages of development, ranging from successful, profitable companies to recently public and privately held companies.  Previously, Dr. Werber was a senior biotech analyst and vice president at SG Cowen Securities Corporation from 2001- 2004.

Dr. Werber has been awarded several accolades for performance and stock picking, he has been highly ranked by Institutional Investor magazine, has received awards from Starmine and was voted among the top five analysts in biotech in the Wall Street Journal’s “Best on the Street” Greenwich survey.  He has frequently been featured as a guest on CNBC, Fox News, Bloomberg News and has been quoted in the Wall Street Journal, New York Times, Fortune, Forbes, Bloomberg and BioCentury.

Dr. Werber earned his B.S. in Biology from Tufts University, cum laude, and a combined M.D./MBA degree from Tufts University School of Medicine where he was a Terner Scholar.

Get In Touch

Start a conversation with Yaron Werber


    Explore related thought leadership, reports, coverage and insights for Yaron Werber.

    Robotic arm holding out a generic pill bottle.

    AI Designing Drugs: Navigating the Hype

    A young female researcher in a lab coat is conducting research on a computer.
    Ahead of the Curve®

    AI In Drug Development: From Hype To The Clinic & Beyond

    A chemist in a lab is taking precaution as he conducts research in full protective gear towards the end of biodefense.
    Ahead of the Curve®

    A New Chapter In Biosecurity: Are We Prepared?